MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
First-in-Human, Randomised, Dose-Finding Single Center Study to evaluate three dose levels of a novel malaria vaccine, MSP3-CRM-Vac4All/ Alhydrogel® : 3 µg, 10 µg and 30 µg
Epistemonikos ID: 525dce4d9c68ab173edfc0ee16b4f6cf3eda0ba8
First added on: May 10, 2024